Post Covid 19 Symptom - A Deadly Combination of Mucormycosis and Diabetes Mellitus in Pandemic Spectrum.

Abstract

Fungal infections, including mucormycosis, aspergillosis and invasive candidiasis, have been reported in patients with severe COVID-19 or those recovering from the disease and have been associated with severe illness and death. India has reported a recent surge in mucormycosis cases. Prevention of COVID-19 associated mucormycosis needs to focus on aiming for better glycaemic control in COVID-19 patients and monitoring the use of systemic corticosteroids in treating severe cases. The survival rate for rhino-cerebral disease in patients without a systemic disease is about 75%; with other diseases is about 20%.; and in pulmonary disease is considered to be fatal. The incidence rate of mucormycosis globally varies from 0.005 to 1.7 per million populations. Successful management of mucormycosis is based on a multimodal approach, including reversal or discontinuation of underlying predisposing factors (if possible), early administration of active antifungal agents at the optimal dose, complete removal of all infected tissues and the use of various adjunctive therapies. Uncontrolled, type II, diabetes is the most common type in diabetic patients with mucormycosis.
Keywords: Mucormycosis, Covid 19, Rhino cerebral mucormycosis